We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest trading session, Humacyte, Inc. (HUMA - Free Report) closed at $0.66, marking a -1.28% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.19%. Elsewhere, the Dow saw a downswing of 0.59%, while the tech-heavy Nasdaq depreciated by 0.05%.
The stock of company has fallen by 28.09% in the past month, lagging the Medical sector's gain of 6.06% and the S&P 500's gain of 0.55%.
Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. In that report, analysts expect Humacyte, Inc. to post earnings of -$0.1 per share. This would mark year-over-year growth of 58.33%. In the meantime, our current consensus estimate forecasts the revenue to be $1.39 million, indicating a 363.33% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.34 per share and a revenue of $8.03 million, demonstrating changes of -30.77% and +293.77%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 13.48% fall in the Zacks Consensus EPS estimate. Humacyte, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 98, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUMA in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Humacyte, Inc. (HUMA - Free Report) closed at $0.66, marking a -1.28% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.19%. Elsewhere, the Dow saw a downswing of 0.59%, while the tech-heavy Nasdaq depreciated by 0.05%.
The stock of company has fallen by 28.09% in the past month, lagging the Medical sector's gain of 6.06% and the S&P 500's gain of 0.55%.
Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. In that report, analysts expect Humacyte, Inc. to post earnings of -$0.1 per share. This would mark year-over-year growth of 58.33%. In the meantime, our current consensus estimate forecasts the revenue to be $1.39 million, indicating a 363.33% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.34 per share and a revenue of $8.03 million, demonstrating changes of -30.77% and +293.77%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 13.48% fall in the Zacks Consensus EPS estimate. Humacyte, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 98, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUMA in the coming trading sessions, be sure to utilize Zacks.com.